HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools Register Now!
Market News Stocks News ETF News Crypto News

EyePoint Pharmaceuticals, Inc.

Contributing Author

Recent Articles by EyePoint Pharmaceuticals, Inc.

Nov-19
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration EYPT GlobeNewswire
Nov-17
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Nov-05
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Nov-03
EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
Oct-29
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 EYPT GlobeNewswire
Oct-16
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Oct-14
EyePoint Announces Pricing of Public Offering EYPT GlobeNewswire
Oct-14
EyePoint Announces Proposed Public Offering of Common Stock EYPT GlobeNewswire
Oct-14
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema EYPT GlobeNewswire
Sep-16
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Aug-26
EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
Aug-18
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Aug-06
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference EYPT GlobeNewswire
Aug-06
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Jul-30
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 EYPT GlobeNewswire
Jul-29
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration EYPT GlobeNewswire
Jul-16
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Jun-16
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-28
EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-27
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration EYPT GlobeNewswire
May-16
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-13
EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-07
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.